GOLD金牌培訓課程快速發展 聯合醫務(00722.HK)年度收入增22.4%及派發末期息2.55港仙
格隆匯9月26日丨聯合醫務(00722.HK)發佈公告，截至2019年6月30日止年度，公司收入5.67億港元，同比增長22.4%；期間純利達1954.9萬港元，每股盈利1.71港仙；末期股息每股2.55港仙，全年派息每股3.2港仙。
收入增長乃主要由於向合約客户提供企業醫療保健解決方案服務以及於香港及澳門向自費患者提供臨牀醫療保健服務所產生的收入由406.9百萬港元（經重列）增加至513.5百萬港元。
公告顯示，於香港及澳門提供臨牀醫療保健服務方面，期間向合約客户提供醫療服務產生的收入由2018財政年度的205.4百萬港元（經重列）增加8.5%至2019財政年度的222.9百萬港元，乃主要由於患者次均診費於2019財政年度增加，以及尋求醫療服務的患者就診次數增加。
期間向合約客户提供牙科服務產生的收入由2018財政年度的17.0百萬港元增加22.4%至2019財政年度的20.8百萬港元，乃主要由於2019財政年度的患者次均診費增加，以及尋求牙科服務的患者就診次數增加。
展望未來，公司預視聯合醫務將為大中華區所有人提供可及、可負擔及可信任的醫療健康服務，並以大灣區為切入點。自從公司上一次彙報以來，GOLD金牌培訓課程及PPP診所達到的發展規模和版圖均贏得中國不同地區政府的讚揚。GOLD金牌培訓課程始於2018年2月，獲廣州市番禺區政府為11名醫生報讀。截至本文刊發日期，GOLD金牌培訓課程的規模已擴展至近200名醫生，他們來自大灣區各大城市，包括廣州、深圳、東莞、中山、珠海、佛山，以及其他城市如北京、上海及天津。目前正在經營以及在建中的PPP診所的數目亦從2018年的僅一間擴展至現時截至本文刊發日期的25間。
公司稱，GOLD金牌培訓課程及PPP診所的擴張只是剛開始。根據政府數據，僅計及大灣區，GOLD金牌培訓課程的規模有可能擴展至超過10,000名醫生，而超過2,000家診所可考慮採納PPP模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
